Press Releases
- Older Australians recognise RSV can be serious, but many don't consider it a personal risk, new research suggests
- GSK Australia wins Great Place To Work® Certification
- AREXVY becomes the first Respiratory Syncytial Virus (RSV) vaccine added to the National Immunisation Program for older Australians
